Fecal microbiota transplantation (FMT) is a rapidly growing therapy aimed at reconstituting the dysbiotic microbiota of a patient with the beneficial stool microbiota of a healthy individual. The efficacy rates of FMT are very robust for recurrent Clostridioides difficile infection in both children and adults. Although complications of FMT have been reported, it is generally believed to be a safe procedure. Novel indications for FMT are being studied, with the hope that ultimately it may be useful for a variety of disorders. As this field continues to grow, however, it is necessary to consider efficacy, safety, and innovation across the lifespan. There are unique concerns regarding FMT as it pertains to children, adults, and the elderly. In this review, we seek to update clinicians, researchers, and regulators on how these factors must be balanced across the lifespan as we move forward with this innovative therapy.
Bibliographical noteFunding Information:
Financial support: This work was supported in part by a North Carolina Children's Promise Research Grant to A.S.G., NIAID K23AI156132 to M.R.N., and NIAID 2R24AI118629-06 to S.A.K.
© 2023 Wolters Kluwer Health. All rights reserved.
- Clostridioides difficile
- fecal microbiota transplant
PubMed: MeSH publication types
- Journal Article